The dramatic changes taking place in many aspects of the medical device industry, from new materials to new business models, are coming together in certain product areas, providing a glimpse of the future device world. One such example is abdominal aortic aneurysm (AAA) surgery, which, having remained virtually unchanged for nearly 40 years, is on the verge of a major transformation, resulting in AAA becoming an important business opportunity. Large device companies are making early investments, trying to pick start-up winners, while emerging companies hope there are some partners left, even though no products are yet available in the US.
by Stephen Levin
For years the medical device industry has been roiling with change at all levels—discoveries in biomaterials and other building blocks leading to the development of new products; the emergence of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
